What is NeuroMetrix Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. NeuroMetrix's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. NeuroMetrix's Operating Income for the
three
months ended in Dec. 2023 was $ -1.86 Mil. NeuroMetrix's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate NeuroMetrix's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
NeuroMetrix Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroMetrix (NAS:NURO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
NeuroMetrix's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-1.86 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $0.09 Mil.
NeuroMetrix's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate NeuroMetrix's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. NeuroMetrix Inc has enough cash to cover all of its debt. Its financial situation is stable.
NeuroMetrix (NeuroMetrix) Business Description
Traded in Other Exchanges
N/A
Address
4B Gill Street, Woburn, MA, USA, 01801
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Executives
| Bradley M Fluegel |
director |
120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
| Thomas T Higgins |
officer: Chief Financial Officer |
|
| Topline Capital Management, Llc |
other: See Explanation in Footnotes |
544 EUCLID STREET, SANTA MONICA CA 90402 |
| Topline Capital Partners, Lp |
10 percent owner |
544 EUCLID STREET, SANTA MONICA CA 90402 |
| Mcbirney Collin |
other: See Explanation in Footnotes |
544 EUCLID STREET, SANTA MONICA CA 90402 |
| Shai Gozani |
director, officer: Chairman, President and CEO |
C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
| Francis X Mcgillin |
officer: Senior VP, Consumer |
C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
| Avermaete David Van |
director |
C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
| Krishnamurthy Balachandran |
officer: S. VP and GM, International |
C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
| Nancy E Katz |
director |
CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502 |
| Neurometrix Inc |
officer: Senior Vice President & GM |
|
| Walter Christensen |
officer: Sr. VP, Global Sales |
C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451 |
| Timothy R Surgenor |
director |
100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035 |
| Deerfield Management Company, L.p. (series C) |
10 percent owner |
345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
| Deerfield Mgmt L.p. |
10 percent owner |
780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
NeuroMetrix (NeuroMetrix) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NURO has been successfully added to your 